Iboga Drug Interactions, Uses, Effectiveness, Safety & More
What is this page for?
First and foremost: how Iboga interacts with medications. The heart of this page is the interaction list — every drug Iboga is known to interact with, and how serious each one is.
But these pages have grown well beyond that into a full monograph — what Iboga is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy
Check Iboga against your medication
Add one medicationIboga Drug Interactions: The Bottom Line
From the HelloPharmacist Editorial Team · Updated July 2026Based on the available evidence, the overall risk of a clinically significant Iboga drug interaction is moderate for most people, and a few combinations call for genuine caution. Nearly all of the hundreds of listed interactions are rated moderate, and one, with paroxetine, is rated major and backed by human study data.
The clearest concern is paroxetine, where a human study found it roughly doubled the body's exposure to iboga's active compound, likely because paroxetine blocks an enzyme the body uses to clear it. Other medicines that block this same enzyme could raise iboga levels in a similar way. Case reports also link iboga to changes in heart rhythm, so combining it with QT interval-prolonging drugs could add to that risk. There is a theoretical chance of too much serotonin when iboga is taken with serotonergic drugs, such as many antidepressants.
A list this long does not mean every combination is harmful. Most entries reflect one shared mechanism, such as effects on an enzyme that processes many medications, or are theoretical concerns from lab research that have not been confirmed in people. The strength of the evidence varies widely across the list.
Based on HelloPharmacist’s Iboga interaction data and reviewed under our editorial standards.
Drugs that interact with Iboga
502 medications have a known interaction with Iboga, graded by severity. Select any drug for the full evidence-based detail.
1 major interaction. These combinations can be clinically significant — best avoided, or used only with close professional supervision. Always check with your pharmacist before combining them with Iboga.
Don’t want to scroll the list? Just ask.
Tell us the medications you take and we’ll check each one against Iboga using our pharmacist-reviewed interaction data.
AI summaries are generated from our Iboga interaction data for education only — always confirm with your pharmacist. How we use AI
No drugs match “”.
What Severity, Likelihood & Evidence Mean
Severity — How Serious It Can Be
- Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
- Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
- Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
- No known interaction. Checked against our sources with nothing documented — not the same as proven safety.
Likelihood — How Well It’s Documented
- Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
- Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
- Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
- Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.
Where This Data Comes From
- Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
- Each drug listed above links to the full report for that exact Iboga combination — clinical detail, likelihood, evidence level, and citations.
- Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
The kinds of drugs Iboga affects
Every type of medication (drug category) Iboga is known to interact with. Open any category for the detail — or search your exact drug in the checker above.
Paroxetine (Paxil)
Theoretically, taking paroxetine with iboga might increase the levels and clinical effects of ibogaine.
One pharmacokinetic study shows that taking paroxetine prior to taking ibogaine, a constituent of iboga, 20 mg increases the exposure to ibogaine and its metabolite noribogaine by 2-fold when compared with taking ibogaine alone. This is thought to be due to inhibition of cytochrome P450 2D6 by paroxetine. Additionally, ibogaine has serotonergic effects and may increase the risk for serotonergic adverse effects when taken with paroxetine.
Anticholinergic Drugs
Theoretically, iboga might decrease the effectiveness of anticholinergic drugs.
In vitro research shows that iboga can inhibit acetylcholinesterase and might increase acetylcholine levels. However, the constituent ibogaine does not appear to have this effect.
Cholinergic Drugs
Theoretically, iboga might have additive effects with cholinergic drugs.
In vitro research shows that iboga can inhibit acetylcholinesterase and might increase acetylcholine levels. However, the constituent ibogaine does not appear to have this effect.
Cytochrome P450 2D6 (Cyp2D6) Inhibitors
Theoretically, taking iboga with CYP2D6 inhibitors might increase the levels and clinical effects of ibogaine.
Ibogaine, the active constituent of iboga, is a substrate of CYP2D6. One pharmacokinetic study shows that taking the CYP2D6 inhibitor paroxetine prior to taking ibogaine 20 mg increases the exposure to ibogaine and its metabolite noribogaine by 2-fold when compared with ibogaine alone.
Qt Interval-Prolonging Drugs
Theoretically, iboga may have an additive effect with drugs that prolong the QT interval.
Numerous case reports suggest that ibogaine, a constituent in iboga, can cause QT interval prolongation.
Serotonergic Drugs
Theoretically, taking iboga with serotonergic drugs might increase levels of serotonin, resulting in additive effects with serotonergic drugs.
Ibogaine, a constituent in iboga, has serotonergic effects. Theoretically, combining serotonergic drugs with iboga might increase the risk of serotonergic side effects, including serotonin syndrome and cerebral vasoconstrictive disorders. Monitor patients for signs of serotonin syndrome and other serotonergic side effects if using iboga with serotonergic drugs.
Iboga: Uses, Safety & Side Effects
Iboga is a Central African shrub whose root bark contains ibogaine, a powerful hallucinogenic compound studied mainly for addiction. It carries serious safety risks, including dangerous heart rhythm changes and deaths, and ibogaine is illegal in the United States and many other countries. We do not recommend its use outside of tightly controlled research settings.

- Scientific name
- Tabernanthe iboga
- Family
- Apocynaceae
- Part used
- Root bark
- Common forms
- Root bark powder, capsules, extracts; the isolated alkaloid ibogaine (a controlled substance in many countries)
- Drug and alcohol addiction
- Opioid withdrawal
- Spiritual and ceremonial rituals
- Fatigue and stimulant effects
- Mood and emotional issues
Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.
Iboga can cause dangerous heart rhythm problems and has been linked to deaths.
There is insufficient reliable information available about the safety of iboga in pregnancy and lactation. Avoid using.
Read the full pregnancy detailThere is insufficient reliable information available about the safety of iboga in pregnancy and lactation. Avoid using.
Read the full breastfeeding detailPregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Overview
Iboga (Tabernanthe iboga) is a shrub native to the rainforests of Central and West Africa, especially Gabon, Cameroon, and the Congo region. Its root bark has been used for centuries in traditional and spiritual practices, including ceremonies of the Bwiti religion.
The root bark contains many natural chemicals called alkaloids. The best known is ibogaine, which has strong hallucinogenic (mind-altering) and stimulant effects. Today Iboga is best known for being studied as a possible treatment for drug and alcohol addiction.
It is important to know that ibogaine is a Schedule I controlled substance in the United States, meaning it is illegal to possess. It is also restricted or banned in several other countries.
How it works
The active alkaloids in Iboga, especially ibogaine, act on many parts of the brain and nervous system. Ibogaine and its breakdown product noribogaine appear to affect chemical messengers such as serotonin and dopamine, and to interact with receptors involved in addiction and reward.
Researchers think these actions may be why Iboga seems to lower cravings and withdrawal symptoms in some studies. However, much of this is based on animal and laboratory research, and the way it works in people is still not fully understood.
The same effects on the brain and on the heart's electrical system are also what make Iboga dangerous.
Does Iboga work?
How to read these evidence grades
Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.
For Iboga, current evidence isn’t strong enough to rate any specific use. The conditions it has been studied for are listed below.
Also studied for 9 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Alcohol use disorder
It is unclear if oral iboga is beneficial for improving abstinence in patients with alcohol use disorder.
Insufficient Reliable Evidence To Rate Cocaine dependence
It is unclear if oral iboga is beneficial for improving abstinence in patients with cocaine dependence.
Insufficient Reliable Evidence To Rate Depression
Although there is interest in using oral iboga for depression, there is insufficient reliable information about the clinical effects of iboga for this condition.
Insufficient Reliable Evidence To Rate Fatigue
Although there is interest in using oral iboga for fatigue, there is insufficient reliable information about the clinical effects of iboga for this purpose.
Insufficient Reliable Evidence To Rate HIV/AIDS
Although there is interest in using oral iboga for HIV/AIDS, there is insufficient reliable information about the clinical effects of iboga for this condition.
Insufficient Reliable Evidence To Rate Hypertension
Although there is interest in using oral iboga for hypertension, there is insufficient reliable information about the clinical effects of iboga for this condition.
Insufficient Reliable Evidence To Rate Influenza
Although there is interest in using oral iboga for influenza, there is insufficient reliable information about the clinical effects of iboga for this condition.
Insufficient Reliable Evidence To Rate Opioid withdrawal
It is unclear if oral iboga is beneficial for opioid withdrawal. Some low-quality clinical research suggests that ibogaine, a constituent of iboga, may reduce withdrawal symptoms and risk of relapse in patients with opioid dependence.
Insufficient Reliable Evidence To Rate Sexual arousal
Although there is interest in using oral iboga to increase sexual arousal, there is insufficient reliable information about the clinical effects of iboga for this use.
Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.
Safety & precautions
Iboga is not considered safe for general use. The biggest concern is its effect on the heart. Ibogaine can slow the heart and cause dangerous changes in heart rhythm (a problem called QT prolongation), which can lead to sudden death. Deaths have been reported in people who took ibogaine, sometimes in informal addiction clinics.
People with heart disease, irregular heartbeats, liver problems, low potassium or magnesium, or mental health conditions are at especially high risk and should not use it. Because of these dangers, any research use is done under close medical and heart monitoring.
Pregnancy and breastfeeding: There is no reliable safety information, and the serious risks make Iboga unsafe. Do not use it if you are pregnant, trying to become pregnant, or breastfeeding.
Remember that ibogaine is illegal to possess in the United States. Always talk with a doctor or pharmacist before considering any unfamiliar supplement.
Side effects
Common short-term effects include hallucinations and vivid dream-like states, nausea and vomiting, loss of coordination, dizziness, anxiety, and trouble walking. These can last many hours.
More serious and potentially life-threatening effects include dangerous heart rhythm changes, very slow heartbeat, seizures, and sudden cardiac death. Several deaths have been linked to ibogaine use, which is why it is considered high-risk.
Iboga: Reported Adverse Effects
Documented safety reports on Iboga from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.
There is currently a limited amount of information available about the adverse effects of whole iboga products or extracts. Orally, ibogaine, a constituent of iboga, can cause serious adverse effects.
Most Common Adverse Effects:
Orally: Arrhythmia, ataxia, diarrhea, hallucinations, headache, nausea, and vomiting.
Cardiac arrest Cardiovascular
Ibogaine is a constituent of iboga. There are numerous case reports of ventricular tachyarrhythmias, cardiac arrest, and QT interval prolongation, some of which resulted in torsade de pointes, in patients who took ibogaine orally. Some of these patients did not have any prior cardiovascular disease. In some cases, cardiac complications resulted in death. One case series suggests that most deaths associated with ibogaine occur in patients with pre-existing co-morbidities, specifically cardiovascular disease, or those taking benzodiazepines, cocaine, methadone, or opiates. Noribogaine, a metabolite of ibogaine, is also associated with cardiotoxic effects, including dose-dependent prolongation of the QT interval.
- O'Connell CW, Gerona RR, Friesen MW, Ly BT. Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. Am J Emerg Med. 2015; 33(7):985.e5-6.
- Vlaanderen L, Martial LC, Franssen EJ, van der Voort PH, Oosterwerff E, Somsen GA. Cardiac arrest after ibogaine ingestion. Clin Toxicol (Phila). 2014;52(6):642-3.
- Asua. Growing menace of ibogaine toxicity. Br J Anaesth. 2013;111(6):1029-30.
- Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360(3):308-9.
- Paling FP, Andrews LM, Valk GD, Blom HJ. Life-threatening complications of ibogaine: three case reports. Neth J Med. 2012;70(9):422-4.
- Pleskovic A, Gorjup V, Brvar M, Kozelj G. Ibogaine-associated ventricular tachyarrhythmias. Clin Toxicol (Phila). 2012;50(2):157.
- Henstra M, Wong L, Chahbouni A, et al. Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. Clin Toxicol (Phila). 2017;55(6):600-602.
- Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302.
- Grogan J, Gerona R, Snow JW, Kao L. Ibogaine consumption with seizure-like episodes, QTc-prolongation, and captured cardiac dysrhythmias. J Emerg Med 2019;57(4):e99-e104.
- 105383 Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study. Addiction 2021.
- Steinberg C, Deyell MW. Cardiac arrest after ibogaine intoxication. J Arrhythm 2018;34(4):455-457.
- Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr Neuropharmacol. 2023;21(11):2178-2194.
- Jalal S, Daher E, Hilu R. A case of death due to ibogaine use for heroin addiction: case report. Am J Addict. 2013;22(3):302.
- Papadodima SA, Dona A, Evaggelakos CI, Goutas N, Athanaselis SA. Ibogaine related sudden death: a case report. J Forensic Leg Med. 2013;20(7):809-11.
- Acimovic T, Atanasijevic T, Denic K, Lukic V, Popovic V, Bogdanovic M. Death due to consumption of ibogaine: case report. Forensic Sci Med Pathol 2021;17(1):126-129.
- Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther Adv Psychopharmacol 2016;6(2):95-8.
Common cold Neurologic/CNS
Ibogaine, a constituent of iboga, taken orally in doses ranging from 10-32 mg/kg may cause confusion, dizziness, dream-like states, hallucinations, and headaches. Ibogaine in doses up to 25 mg/kg has been associated with cases of extreme sensitivity to color and sound, sweating, cold sensations, increased energy and appetite, insomnia, and a strong aphrodisiac effect. Severe transient ataxia was reported in all patients in an observational study with full remission within 24 hours.
In one case report, 3.8 grams of ibogaine taken over a few hours resulted in dissociation and motor agitation in a 33-year-old heroin addict. There have also been three case reports of mania in patients taking unspecified doses of ibogaine, often in combination with various other medications. A 43-year old female who was using ibogaine for heroin and benzodiazepine addiction was admitted to the emergency room unconscious with idiopathic encephalopathy; it was unclear if the encephalopathy was due to ibogaine or concurrent hypoxia. In another case report, a 61-year-old male developed an alteration in consciousness level within 12 hours of ingesting a single dose of 5.6 grams of ibogaine. In another case report, a 34-year-old female developed hallucinations, seizure activity, and CNS depression shortly after taking ibogaine 2 grams. Confusion persisted after four days in hospital requiring transport to a psychiatric unit.
- Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.
- Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. J Psychedelic Stud 2017;1(2):65-73.
- Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr Neuropharmacol. 2023;21(11):2178-2194.
- Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994 Jul-Aug;11(4):379-85.
- 105383 Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study. Addiction 2021.
- O'Connell CW, Gerona RR, Friesen MW, Ly BT. Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. Am J Emerg Med. 2015; 33(7):985.e5-6.
- Marta CJ, Ryan WC, Kopelowicz A, Koek RJ. Mania following use of ibogaine: A case series. Am J Addict. 2015;24(3):203-5.
- Paling FP, Andrews LM, Valk GD, Blom HJ. Life-threatening complications of ibogaine: three case reports. Neth J Med. 2012;70(9):422-4.
- Steinberg C, Deyell MW. Cardiac arrest after ibogaine intoxication. J Arrhythm 2018;34(4):455-457.
- Grogan J, Gerona R, Snow JW, Kao L. Ibogaine consumption with seizure-like episodes, QTc-prolongation, and captured cardiac dysrhythmias. J Emerg Med 2019;57(4):e99-e104.
Diarrhea Gastrointestinal
Ibogaine, a constituent of iboga, taken orally may cause nausea and vomiting in some individuals. Doses up to 25 mg/kg have been associated with diarrhea. In one case report, a 61-year-old male developed hypokalemia following heavy vomiting and diarrhea within 6-12 hours of ingesting a single dose of 5.6 grams of ibogaine. However, a meta-analysis of 2 small clinical trials shows no greater risk of nausea between ibogaine/noribogaine and placebo among adults being treated for substance use disorder.
- Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.
- Alper KR, Lotsof HS, Frenken GM, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999 Summer;8(3):234-42.
- Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994 Jul-Aug;11(4):379-85.
- 105383 Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study. Addiction 2021.
- Steinberg C, Deyell MW. Cardiac arrest after ibogaine intoxication. J Arrhythm 2018;34(4):455-457.
- Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. J Psychedelic Stud 2017;1(2):65-73.
- Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr Neuropharmacol. 2023;21(11):2178-2194.
Myasthenia gravis Musculoskeletal
Ibogaine is a constituent of iboga. When taken orally in doses ranging from 12-29 mg/kg, ibogaine may cause ataxia, tremors, and muscular pain. Noribogaine, the metabolite of ibogaine, is thought to be less likely to cause tremors.
- Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000.
- Alper KR, Lotsof HS, Frenken GM, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999 Summer;8(3):234-42.
- Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994 Jul-Aug;11(4):379-85.
- Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr Neuropharmacol. 2023;21(11):2178-2194.
- Henstra M, Wong L, Chahbouni A, et al. Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. Clin Toxicol (Phila). 2017;55(6):600-602.
Adverse-effects data: Natural Medicines, Therapeutic Research Center
Dosing
There is no established safe or standard dose of Iboga or ibogaine for any condition. Because the compound is unpredictable and can harm the heart, doses cannot be recommended here.
Ibogaine is a controlled substance in the United States, so it cannot be legally bought or used as a supplement. Do not attempt to dose yourself with Iboga. If you are struggling with addiction, speak with a doctor or pharmacist about safe, proven treatment options.
Iboga & Pregnancy
Iboga & Breastfeeding
© 2026 Therapeutic Research Center
Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center
References & further reading
The 26 references that drive our Iboga monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Glick SD, Maisonneuve IS. Mechanisms of antiaddictive actions of ibogaine. Ann N Y Acad Sci 1998;844:214-26.
- Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. PubMed
- Marta CJ, Ryan WC, Kopelowicz A, Koek RJ. Mania following use of ibogaine: A case series. Am J Addict. 2015;24(3):203-5. PubMed
- O'Connell CW, Gerona RR, Friesen MW, Ly BT. Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. Am J Emerg Med. 2015; 33(7):985.e5-6. PubMed
- Vlaanderen L, Martial LC, Franssen EJ, van der Voort PH, Oosterwerff E, Somsen GA. Cardiac arrest after ibogaine ingestion. Clin Toxicol (Phila). 2014;52(6):642-3. PubMed
- Asua. Growing menace of ibogaine toxicity. Br J Anaesth. 2013;111(6):1029-30. PubMed
- Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360(3):308-9. PubMed
- Jalal S, Daher E, Hilu R. A case of death due to ibogaine use for heroin addiction: case report. Am J Addict. 2013;22(3):302. PubMed
- Paling FP, Andrews LM, Valk GD, Blom HJ. Life-threatening complications of ibogaine: three case reports. Neth J Med. 2012;70(9):422-4.
- Papadodima SA, Dona A, Evaggelakos CI, Goutas N, Athanaselis SA. Ibogaine related sudden death: a case report. J Forensic Leg Med. 2013;20(7):809-11. PubMed
- Pleskovic A, Gorjup V, Brvar M, Kozelj G. Ibogaine-associated ventricular tachyarrhythmias. Clin Toxicol (Phila). 2012;50(2):157. PubMed
- Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993-1000. PubMed
- Alper K, Reith ME, Sershen H. Ibogaine and the inhibition of acetylcholinesterase. J Ethnopharmacol. 2012;139(3):879-82. PubMed
- Alper KR, Lotsof HS, Frenken GM, et al. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999 Summer;8(3):234-42. PubMed
- Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994 Jul-Aug;11(4):379-85. PubMed
- Henstra M, Wong L, Chahbouni A, et al. Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. Clin Toxicol (Phila). 2017;55(6):600-602. PubMed
- Glue P, Winter H, Garbe K, et al. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20?mg dose of ibogaine in healthy volunteers. J Clin Pharmacol. 2015;55(6):680-7. PubMed
- Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302. PubMed
- Rodriguez P, Urbanavicius J, Prieto JP, et al. A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats. ACS Chem Neurosci 2020;11(11):1661-1672. PubMed
- Grogan J, Gerona R, Snow JW, Kao L. Ibogaine consumption with seizure-like episodes, QTc-prolongation, and captured cardiac dysrhythmias. J Emerg Med 2019;57(4):e99-e104. PubMed
- Acimovic T, Atanasijevic T, Denic K, Lukic V, Popovic V, Bogdanovic M. Death due to consumption of ibogaine: case report. Forensic Sci Med Pathol 2021;17(1):126-129. PubMed
- 105383 Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study. Addiction 2021. PubMed
- Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther Adv Psychopharmacol 2016;6(2):95-8. PubMed
- Steinberg C, Deyell MW. Cardiac arrest after ibogaine intoxication. J Arrhythm 2018;34(4):455-457. PubMed
- Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. J Psychedelic Stud 2017;1(2):65-73. PubMed
- Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr Neuropharmacol. 2023;21(11):2178-2194. PubMed
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Iboga: Common Questions
What is Iboga used for, and does it work?
Does Iboga interact with prescription medications?
How are Iboga interactions rated?
Is it safe to take Iboga with my medications?
Where does this Iboga interaction information come from?
What is Iboga used for?
Is Iboga safe to take?
Is Iboga legal?
Can I take Iboga while pregnant or breastfeeding?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Have a question about Iboga?
Our pharmacists answer your medication & supplement questions — free.